Skip to main content
Home
  • About
    • About the Navigator
    • Navigator FAQs
  • Guides
    • For Patients and Caregivers
    • For Physicians and Healthcare Providers
    • For Companies and Sponsors
  • Company Directory
    • View Company Directory
    • Submit Company Information
  • Resources
  • Expanded Access eRequest
  • facebook
  • twitter
  • linkedin
  • youtube
Home
  • About
    • About the Navigator
    • Navigator FAQs
  • Guides
    • For Patients and Caregivers
    • For Physicians and Healthcare Providers
    • For Companies and Sponsors
  • Company Directory
    • View Company Directory
    • Submit Company Information
  • Resources
  • Expanded Access eRequest

Epetraborole in Patients With Mycobacterium Abscessus Lung Disease

  • Read more about Epetraborole in Patients With Mycobacterium Abscessus Lung Disease

National Human Genome Research Institute

By jpalfreyman on Tue, 12/23/2025 - 22:27
  • Read more about National Human Genome Research Institute

Neurodawn Pharmaceutical Co., Ltd.

By jpalfreyman on Tue, 12/23/2025 - 22:22
  • Read more about Neurodawn Pharmaceutical Co., Ltd.

Study of VYD2311 for the Prevention of COVID-19

  • Read more about Study of VYD2311 for the Prevention of COVID-19

Sonlicromanol in Post-COVID

  • Read more about Sonlicromanol in Post-COVID

A Study of LY4170156 in Participants With Selected Advanced Solid Tumors

  • Read more about A Study of LY4170156 in Participants With Selected Advanced Solid Tumors

Predictors of Long-Term Evolution in Long COVID; 4-Year Follow-Up. (BioICOPER Follow-up Study)

  • Read more about Predictors of Long-Term Evolution in Long COVID; 4-Year Follow-Up. (BioICOPER Follow-up Study)

Maternal Health Assessment in Pediatric Care

  • Read more about Maternal Health Assessment in Pediatric Care

A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Part B) Ovarian Cancer

  • Read more about A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Part B) Ovarian Cancer

Comparative Immunogenicity of Respiratory Virus Vaccines (CIRV2) Study

  • Read more about Comparative Immunogenicity of Respiratory Virus Vaccines (CIRV2) Study

Pagination

  • First page « First
  • Previous page ‹ Previous
  • …
  • Page 15
  • Page 16
  • Page 17
  • Page 18
  • Current page 19
  • Page 20
  • Page 21
  • Page 22
  • Page 23
  • …
  • Next page Next ›
  • Last page Last »
Subscribe to

Subscribe for updates from the Reagan-Udall Foundation for the FDA

Subscribe
(202) 849 - 2075
1333 New Hampshire Ave, NW
Suite 420
Washington, DC 20036
navigator@reaganudall.org
  • facebook
  • twitter
  • linkedin
  • youtube

© Reagan-Udall Foundation for the FDA
© Reagan-Udall Foundation for the FDA